Neupogen (filgrastim) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Neupogen (filgrastim) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historic period can be attributed to the increasing prevalence of cancer, greater awareness of chemotherapy-induced neutropenia, improvements in healthcare infrastructure, early approvals for Neupogen biosimilars, and rising global healthcare expenditures.

The growth projected for the forecast period is driven by the rising demand for cost-effective treatments for neutropenia, expanded healthcare access in emerging markets, increased government support for biosimilar adoption, a stronger emphasis on personalized medicine, and the growing elderly population. Key trends during the forecast period include increased investments in research and development of biosimilars, advancements in drug delivery systems for neutropenia treatments, growing partnerships for oncology drug commercialization, enhanced focus on patient affordability programs, and the development of next-generation G-CSF products.

The increasing prevalence of various diseases is expected to drive the growth of the neupogen (filgrastim) market in the coming years. Diseases, whether caused by infections, genetic factors, environmental influences, or lifestyle choices, have become more prevalent due to factors such as aging populations, sedentary lifestyles, pollution, and poor dietary habits. Neupogen (filgrastim) plays a crucial role in managing chemotherapy-induced neutropenia by stimulating the production of neutrophils, which helps enhance the immune system’s ability to combat infections in patients with weakened immunity. This is essential in reducing hospitalizations and allowing continuous cancer treatments. According to Allergy UK, over 21 million people in the UK suffered from allergies in 2022, a number expected to rise, and nearly 3.5 million people in the UK are projected to live with cancer by 2025, highlighting the growing need for treatments like neupogen. These trends will significantly drive demand for neupogen (filgrastim) in the future.

Government initiatives for research and development in healthcare are expected to propel the neupogen (filgrastim) market. Governments worldwide are increasingly focusing on funding healthcare research and expanding life sciences manufacturing to improve the availability of medical treatments. For example, in 2022, the UK government announced £260 million in funding to support NHS-led research into new diagnostics and treatments and to expand life sciences manufacturing. Such investments foster innovation and provide greater access to advanced therapies, which directly supports the growth of treatments like neupogen.

A key trend in the neupogen (filgrastim) market is the development of biosimilars, which offer cost-effective alternatives to the original drug while maintaining similar safety, efficacy, and structural characteristics. Filgrastim biosimilars are designed to mimic Neupogen, stimulating neutrophil production to treat chemotherapy-induced neutropenia. A notable development in this area occurred in November 2022, when Amneal Pharmaceuticals and Kashiv Biosciences launched Releuko (filgrastim-ayow), a biosimilar to Neupogen, in the U.S. Releuko provides both intravenous and subcutaneous formulations, offering flexibility in dosing and improving accessibility to essential treatments. This trend of biosimilars is increasing the affordability and availability of chemotherapy support medications, driving further growth in the Neupogen market.

The key players operating in the neupogen (filgrastim) market is Amgen Inc.

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neupogen (filgrastim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neupogen (filgrastim) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells in the bone marrow. It is used to prevent infections in patients with neutropenia resulting from chemotherapy, bone marrow transplantation, or specific medical conditions.

The primary drug types of neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are sourced from living organisms and require complex manufacturing processes to achieve targeted therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and other conditions. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The neupogen (filgrastim) market research report is one of a series of new reports that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.